Rectal Cancer after Prostate Radiation: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Oncology
Contributor:
Dana M. Omer
,
Hannah M. Thompson
,
Floris S. Verheij
,
Jonathan B. Yuval
,
Roni Rosen
,
Nathalie R. A. Beets
,
Anisha Luthra
,
Paul B. Romesser
,
Philip B. Paty
,
Julio Garcia-Aguilar
,
Francisco Sanchez-Vega

Radiation therapy is commonly used in the treatment of prostate cancer, but it is a carcinogen itself. Long-term survivors of prostate cancer who were treated with pelvic radiotherapy have been reported to be at increased risk for developing rectal cancer compared to those treated with surgery. The molecular features of radiation-associated rectal cancer have not been fully investigated, and survival is lower compared to non-irradiated rectal cancer patients. Ultimately, it is unclear whether the worse outcomes are related to differences in patient characteristics, treatment-related factors, or tumor biology. 

  • radiation
  • rectal cancer
  • radiation-associated rectal cancer
  • colorectal surgery
  • oncology
  • surgical oncology
  • radiation oncology

1. The Limitations of Studies Investigating Radiation-Associated Rectal Cancer

The literature on radiation-associated rectal cancer (RARC) remains inconclusive and often contradictory. This is partly due to the low prevalence of the disease, inconsistencies in defining the latency period between the use of radiation and the diagnosis of rectal adenocarcinoma, and variations in study design and methodology. Furthermore, results are affected by patient selection criteria and duration of follow-up. Several studies also analyzed RARC alongside other radiation-induced cancers, and so the unique characteristics of rectal cancer are often overlooked. Most studies reporting the incidence of RARC are based on large epidemiologic databases and tumor registries that contain large numbers of patients but often lack important details such as radiation dosages or radiation fields.

2. Radiotherapy Is a Pillar of Prostate Cancer Treatment

Radiotherapy is an integral part of treatment for over half of all oncologic malignancies and has impacted the recurrence and survival rates of several cancers, including prostate cancer [1][2]. It is estimated that more than 260,000 new prostate cancers are diagnosed annually within the United States. It is the most common non-cutaneous cancer in males, with a steadily rising incidence in all age groups [3]. The implementation of screening programs contributes to an increasing number of patients diagnosed with prostate cancer at an earlier age, with 32% of new diagnoses occurring between the ages of 55 and 64 years [4]. Approximately 1 in 4 of all prostate cancer patients undergo radiotherapy [5], and it is an accepted treatment modality for prostate cancer groups of all risks and all ages [6]. Radiotherapy is often utilized in older, more frail patients and those with comorbidities that preclude surgery. A variety of therapeutic dosages are available and have been associated with decreased rates of biochemical failure, distant recurrence, and the need for salvage therapy [7]. However, the improvements in outcomes come at the cost of developing treatment-related toxicity, [8] including chronic genitourinary, sexual, and gastrointestinal dysfunction [9]. Patients may also develop additional primary cancers, such as RARC [10][11], which has been reported to develop in approximately 0.48% of prostate cancer patients treated with pelvic radiotherapy [12]. The 10-year overall survival of prostate cancer is over 80% [4][13][14]; therefore, many prostate cancer survivors who were treated with pelvic radiotherapy are at risk for developing radiation-associated second malignancies.
The treatment of prostate cancer can include a combination of external beam radiotherapy (EBRT) and a brachytherapy boost, or with brachytherapy alone [6]. Brachytherapy involves the implantation of permanent radioactive seeds of either low-dose iodine-125 or palladium-103 for low-dose rate brachytherapy, or the placement of temporary iridium-192 catheters for high-dose treatment. Brachytherapy alone is supposed to be associated with less radiation exposure to the surrounding organs compared to EBRT [15]. However, brachytherapy has also been associated with the development of RARC. EBRT results in radiation exposure to the bladder neck, the anterior rectal wall, and the penile bulb. Patients treated with EBRT have been reported to be at a higher risk of RARC than patients treated with brachytherapy [16][17][18]. In summary, early detection of prostate cancer, a propensity to treat young patients in general, the increased use of radiation, and prolonged survival increase the risk for prostate cancer patients developing RARC.

3. Direct Beam Radiation Damages Surrounding Organs

Radiation-associated malignancies have been reported after treatment for breast, hematologic, gynecologic, and prostate cancers; however, the radiation dose which induces a malignancy remains unknown and the mechanism of carcinogenesis in the surrounding tissues has not been identified [19][20][21][22][23][24][25]. Ionizing radiation acts by targeting DNA, resulting in direct double-strand breaks, and by the production of free radicals, which indirectly induce DNA damage [1][26]. During treatment, patients are exposed to both primary and secondary radiation. Primary radiation occurs when cells are exposed to direct beam radiation. This includes tissue that is in the path of the photon beam and receives high doses of radiation. Scatter radiation (secondary radiation) occurs when photons spread out in different directions as it travels through the body. Ultimately, the surrounding tissues are exposed to both primary and secondary radiation, which may accumulate sublethal DNA damage in the cells [24]. Patients treated with EBRT of the prostate will have radiation exposure to the rectum in both of these ways.

4. The Incidence and Risk of Developing RARC

Both prostate and rectal cancer are common diagnoses. In the United States, the lifetime risk of developing prostate cancer is 11%, [27] and 0.65–1.2% for rectal cancer [28]. The lifetime risk of developing RCRPC remains unknown, and the literature appears to be conflicted in reporting associations between rectal cancer and prostate radiotherapy. Most studies investigating rectal cancer in patients who had undergone radiotherapy for prostate cancer (RCRPC)—compared to either rectal cancer in patients who had undergone treatment for prostate cancer without radiotherapy (RCNRPC) or rectal cancer in patients without a history of prostate cancer (RCNAPC)—are performed using population-based cancer registries, and the discrepancies in outcomes can be explained by differences in methodology. Most importantly, variations in latency period cutoffs (time from prostate irradiation to diagnosis of rectal cancer), patient follow-up, and radiation modalities can drastically affect the observations reported. Smaller studies are also limited by sample size.
The more recent literature addresses the issues of latency periods, patient follow-up, and sample size. Baxter et al. performed a population-based study and compared 30,552 prostate cancer patients treated with radiotherapy with 55,263 patients treated with prostatectomy. The authors found a 70% increased risk of developing rectal cancer [HR 1.70 (95% CI 1.4–2.2); p < 0.0001] in prostate cancer patients treated with radiation compared to those treated with surgery [29]. Patients with a latency period shorter than five years were excluded, and the mean length of follow-up was approximately nine years. Moon et al. performed a similar analysis using the SEER database and found that the odds of developing rectal cancer were higher in patients treated with prostate EBRT compared to non-irradiated patients [OR 1.60 (95% CI 1.29–1.99); p < 0.05]. The authors included patients with a latency period of at least five years, and median follow-up was 10 years [16]. Similar results have also been reported by Rombouts et al., using the Netherlands Cancer Registry; the incidence of rectal cancer in patients with prostate cancer treated with radiation therapy compared to patients treated without radiation was SIR 1.20 (95% CI 1.10–1.30) vs. 0.99 (95% CI 0.91–1.06), respectively [30]. Huo et al. highlighted the importance of appropriate patient follow-up in studies investigating radiation-induced malignancies. The authors performed a SEER study of 635,910 patients and found that the incidence of RCRPC did not differ from RCNRPC when the analysis included patients with a short latency period [SIR 1.06 vs. 0.92, p = 0.08]; however, they found a difference between groups when patients with a latency period of >10 years were compared [SIR 1.44 vs. 0.76, p < 0.0001] [31].
The risk of developing rectal cancer does not appear to increase in prostate cancer patients who underwent radical prostatectomy without radiotherapy [17][31][32]. For example, Yang et al. identified 1,491 RARC patients from 573,306 people treated with pelvic radiation for prostate, bladder, uterine, cervical, or ovarian cancer. At the end of follow-up, the authors reported that the incidence of RARC was highest in patients treated with a combination of EBRT and BT [SIR 1.85 (95% CI: 1.60–2.14)], followed by EBRT alone [SIR 1.22 (95% CI: 1.09–1.36)], and the risk was lower in patients treated without pelvic radiation SIR = 0.85, 95% CI: 0.80–0.91)] [25]. This observation suggests that radiation is independently playing a role in tumorigenesis of rectal cancer. Furthermore, there is no reported increased incidence of metachronous colon cancer in prostate cancer patients treated with or without radiation. Baxter et al. investigated the risk of colorectal cancer in a cohort of 30,552 prostate cancer patients treated with or without radiotherapy using the SEER database [29]. The authors stratified the risk of colorectal cancer into three anatomical groups: (A) definitely irradiated sites (the rectum); (B) potentially irradiated sites, such as the rectosigmoid colon, sigmoid colon, and cecum; and (C) non-irradiated large bowel, such as the transverse colon. The authors found a 70% increase in the risk of developing rectal cancer (HR 1.7, 95% CI 1.4–2.2) compared to patients who underwent radical prostatectomy only. There was no significant risk to the potentially irradiated and non-irradiated sites. Overall, there is strong evidence that the incidence of RARC appears to rise with time [33] and that RARC is a real concern and should be considered for young patients diagnosed with prostate cancer.

5. The Molecular Profile of RARC Remains Unknown

The genomic landscape of spontaneous colorectal cancer has been extensively characterized [34][35][36]. Colorectal cancers are associated with one of two forms of genetic instability, either chromosomal instability (CIN) or microsatellite instability (MSI), characterized by the accumulation of mutations in several oncogenes and tumor mutation genes [37][38]. However, the molecular profile of RARC remains unknown. Tsuji et al. analyzed the genetic aberrations of 5 RARC patients treated with pelvic radiotherapy for cervical cancer. None of the tumors had microsatellite instability based on standard enriched-PCR sequence analysis. Kras mutations were detected in two samples, and p53 in another two carcinomas. The authors concluded that RARC developed along the CIN pathway that characterizes the multistep dysplasia–adenoma–carcinoma sequence, rather than the mutator phenotype pathway [39][40]. Although the sample size was small and no definitive conclusions should be made, this study highlights the concept that radiation-induced malignancies may have interesting and unique molecular features compared to their non-radiation-induced counterparts. 

6. Assessment, Surveillance and Diagnosis

Patients with RARC may be entirely asymptomatic and diagnosed incidentally during follow-up for the primary malignancy, or as a result of screening for colorectal cancer. Symptomatic patients most commonly present with overt or occult rectal bleeding resulting in iron deficiency anemia, hematochezia, discharge, urgency, diarrhea, and pain. However, these symptoms are also common in patients who develop radiation proctitis after pelvic radiotherapy [41]. Fibrosis may result in strictures, and patients may present with constipation or obstruction. A change in the gut microbiota may result in malabsorption [42]. Bulky lesions can cause changes in bowel habits, obstruction, or tenesmus.
The U.S. Preventive Services Task Force does not explicitly recognize prior pelvic irradiation as a risk factor for the development of rectal cancer [43]. The National Comprehensive Cancer Network recommends increased frequency of colorectal cancer screening in patients with previous abdominal, flank, and pelvic RT of ≥20 Gy [44]. Several authors support including history of pelvic irradiation as a risk factor for colorectal cancer and recommend more frequent surveillance compared to the average population. They also suggest a possible improvement in survival [18][29][45][46][47].
Endoscopy with biopsy remains the gold standard for the diagnosis of rectal cancer. Some patients may develop RARC in a background of chronic radiation-related changes, but this is not always the case [46]. When chronic proctitis is present, telangiectasia is the most common treatment-related change after EBRT to the prostate. It has been observed to frequently develop along the anterior distal rectal wall. Mucosal congestion, ulcerations, strictures, and necrosis have also been observed in these patients [48]. When radiation proctitis is present, diagnosing RARC becomes more difficult because smaller, ulcerated tumors are difficult to identify.
Like other rectal cancers, patients with RARC are also staged using computed tomography (CT) and magnetic resonance imaging (MRI) or endoscopic ultrasound. The purpose of a CT scan is to evaluate the chest, abdomen, and pelvis for distant metastasis. Some patients undergo an endoscopic ultrasound of the rectum to assess the primary tumor. Post-radiation changes in the rectal wall and surrounding structures may increase the difficulty of staging rectal cancer, [49] and the presence of radiation seeds may cause artifacts that can impair the interpretation of rectal MRI. Ultimately, the accuracy of imaging studies for staging locoregional RARC remains unknown.

7. Treatment, Outcomes and Prognosis of RARC

Surgery is the primary treatment for rectal cancer. Early-stage spontaneous rectal cancer is often treated with surgery alone, either local excision or total mesorectal excision (TME). Radiotherapy delivered as either chemoradiation (45–50 Gy in 25–28 fractions combined with sensitizing fluoropyrimidines) or short-course radiation (25 Gy delivered in 5 fractions) is commonly indicated in patients with locally advanced rectal cancer to reduce the risk of local recurrence after TME surgery. However, radiotherapy is also commonly delivered before local excision in patients with early-stage rectal cancer who want to avoid the consequences of TME surgery [50]. The finding that patients with a complete response to neoadjuvant therapy can forgo TME surgery and achieve sustained organ preservation has emphasized the importance of radiotherapy in rectal cancer [51].
The use of radiotherapy in rectal cancer patients with a history of previous pelvic radiation is controversial. The idea of repeating radiation therapy of a potential RARC seems counterintuitive. The benefits of reirradiation for local tumor control in patients with either early-stage or locally advanced RARC have not been proven. Furthermore, pelvic reirradiation is associated with the risk of severe toxicities such as severe radiation proctitis, genitourinary bleeding, bone fractures, bowel, urinary, and sexual dysfunction, and pelvic pain [52][53]. Reirradiation followed by local excision could lead to delayed healing of the rectal wall wound and rectourethral or rectovaginal fistula [54]. There are also concerns that the pre-existing radiation-related fibrosis could be enhanced by reirradiation, further increasing the technical difficulty of the TME operation, and impacting its quality. Reirradiation may increase the anastomotic leak rate in patients who undergo a sphincter-saving procedure and the rate of perineal wound complications in patients requiring an abdominoperineal excision of the rectum [55][56][57]. These considerations highlight the complexity of selecting appropriate patients for neoadjuvant rectal radiation. Systemic chemotherapy is probably the neoadjuvant therapy of choice in patients with locally advanced RARC. However, accelerated hyper-fractionated radiation with concomitant capecitabine remains an option for RARC patients with an incomplete response to systemic chemotherapy [58][59][60][61].
Surgery for RARC patients also deserves special technical considerations. Most of the tumors are located in the distal rectum, often in the anterior wall adjacent to the previously irradiated prostate. Given the absence of the mesorectum in the anterior wall of the distal rectum, tumors usually involve or threaten the circumferential resection margin, [62] often requiring neoadjuvant therapy, extended surgery, or both. Considering the limited neoadjuvant options for previously irradiated patients and the impaired healing of heavily irradiated prostatic and urethral tissue, an extended resection often requires pelvic exenteration, a procedure associated with significant mortality and morbidity rates in older patients with comorbid conditions. Patients diagnosed with RARC who cannot undergo surgery require alternative treatment approaches. Some examples include chemotherapy, tumor ablation, pelvic reirradiation using high dose endorectal brachytherapy, and diverting stomas; however, the literature supporting the use of these alternative approaches is limited.

8. The Oncologic Outcomes of RARC

In 2019, Rombouts et al. used data retrieved from the Netherlands Cancer Registry in order to compare the five-year overall survival of 618 rectal cancer patients previously treated with pelvic radiation to 750 patients treated without radiotherapy [30]. The authors found no differences in survival between the two groups (HR 0.94, 95% CI 0.79–1.11). Yang et al. published SEER data which compared the five-year survival of patients with RARC to primary rectal cancer without a previous pelvic cancer or pelvic radiotherapy (called the “PRCO” group). The authors performed propensity score matching of the two groups based on gender, age, race, stage, and treatment with chemotherapy, radiation, and surgery. In this study, the survival of rectal cancer patients treated with radiation and surgery were not directly compared. However, RARC was associated with lower five-year overall survival than the matched PRCO group (p < 0.001, HR 1.33 (95% CI 1.14–1.55). Furthermore, the RARC group was also found to have shorter rectal cancer-specific survival (p = 0.004, HR 1.30, 95% CI 1.07–1.58) compared to their matched, non-irradiated counterparts. However, a difference in rectal cancer-specific survival (RCSS) was not observed between patients treated without pelvic radiation and matched patients without pelvic cancer (p = 0.116; HR 1.11, 95% CI 0.97–1.28), suggesting that prognosis is worse in patients previously treated with pelvic radiotherapy [18]. Both groups were well matched, implying that the lower survival of the RARC group may be attributed to differences in tumor biology and the use of radiation. Similar analyses have been attempted in female patients diagnosed with rectal cancer after radiotherapy for cervical cancer, but they are limited by sample size [63]. Hung et al. identified 45 patients with rectal cancer after radiotherapy of the cervix. The authors reported a five-year overall survival rate of 28.7% in the 29 patients who underwent previous cervical radiotherapy compared to 67.2% in the non-irradiated cohort (p = 0.081). Despite such efforts, local regrowth and recurrence rates, distant recurrence rates, and disease-free survival have not yet been reported in the literature.

9. Risk Reduction and Prevention

Preventative measures to reduce the exposure of the surrounding organs to radiation may help to reduce the incidence of RARC. These include minimizing exposure based on radiotherapy modality, and individualized dose adjustments using dose–volume histograms [64]. Rectal spacers can be used to temporarily displace the rectum posteriorly, reducing the dosage of radiation absorbed by the rectum [65][66][67]. Other radiotherapy modalities to treat prostate cancer should also be considered. For example, proton-beam radiation therapy has been shown to be associated with a lower risk of second cancer compared to intensity-modulated radiotherapy (OR 0.31, 95% CI 0.26–0.36, p < 0.0001) [68]. Furthermore, bone marrow irradiation or bone-sparing pelvic radiotherapy may be utilized, although its use in patients with RARC and effects on their immune system have yet to be studied. Patients with germline mutations at risk for additional cancers should be identified early in their clinical course, and follow-ups should be frequent [69]. Smokers should be advised to quit, diet modifications should be encouraged, and patients should be educated on the possibility of developing another cancer.

This entry is adapted from the peer-reviewed paper 10.3390/cancers15082214

References

  1. Baskar, R.; Dai, J.; Wenlong, N.; Yeo, R.; Yeoh, K.-W. Biological response of cancer cells to radiation treatment. Front. Mol. Biosci. 2014, 1, 24.
  2. Barton, M.B.; Jacob, S.; Shafiq, J.; Wong, K.; Thompson, S.R.; Hanna, T.P.; Delaney, G.P. Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. Radiother. Oncol. 2014, 112, 140–144.
  3. Bleyer, A.; Spreafico, F.; Barr, R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer 2020, 126, 46–57.
  4. National Cancer Institute. Seer Prostate. Available online: http://seer.cancer.gov/registries/ (accessed on 20 May 2022).
  5. Martin, N.E.; D’Amico, A.V. Progress and controversies: Radiation therapy for prostate cancer. CA Cancer J. Clin. 2014, 64, 389–407.
  6. National Comprehensive Cancer Network. Available online: http://www.nccn.org/ (accessed on 19 May 2022).
  7. Kamran, S.C.; D’Amico, A.V. Radiation therapy for prostate cancer. Hematol. Oncol. Clin. N. Am. 2020, 34, 45–69.
  8. Michalski, J.M.; Moughan, J.; Purdy, J.; Bosch, W.; Bruner, D.W.; Bahary, J.-P.; Lau, H.; Duclos, M.; Parliament, M.; Morton, G.; et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients with Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018, 4, e180039.
  9. Michaelson, M.D.; Cotter, S.E.; Gargollo, P.C.; Zietman, A.L.; Dahl, D.M.; Smith, M.R. Management of complications of prostate cancer treatment. CA Cancer J. Clin. 2008, 58, 196–213.
  10. Dracham, C.B.; Shankar, A.; Madan, R. Radiation induced secondary malignancies: A review article. Radiat. Oncol. J. 2018, 36, 85–94.
  11. Sasaki, K.; Ishihara, S.; Hata, K.; Kiyomatsu, T.; Nozawa, H.; Kawai, K.; Tanaka, T.; Nishikawa, T.; Otani, K.; Yasuda, K.; et al. Radiation-associated colon cancer: A case report. Mol. Clin. Oncol. 2017, 6, 817–820.
  12. Rombouts, A.J.M.; Hugen, N.; Van Beek, J.J.P.; Poortmans, P.M.P.; De Wilt, J.H.W.; Nagtegaal, I.D. Does pelvic radiation increase rectal cancer incidence?—A systematic review and meta-analysis. Cancer Treat. Rev. 2018, 68, 136–144.
  13. Brenner, H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002, 360, 1131–1135.
  14. Siegel, D.A.; O’Neil, M.E.; Richards, T.B.; Dowling, N.F.; Weir, H.K. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity—United States, 2001–2017. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1473–1480.
  15. Zelefsky, M.J.; Housman, D.M.; Pei, X.; Alicikus, Z.; Magsanoc, J.M.; Dauer, L.T.; St Germain, J.; Yamada, Y.; Kollmeier, M.; Cox, B.; et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012, 83, 953–959.
  16. Moon, K.; Stukenborg, G.J.; Keim, J.; Theodorescu, D. Cancer incidence after localized therapy for prostate cancer. Cancer 2006, 107, 991–998.
  17. Nieder, A.M.; Porter, M.P.; Soloway, M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: A population based cohort study. J. Urol. 2008, 180, 2005–2009, discussion 2009.
  18. Yang, R.; Guan, X.; Liu, E.; Wei, R.; Zhao, Z.; Chen, H.; Liu, Z.; Yang, M.; Jiang, Z.; Wang, X. Risk and prognosis of secondary rectal cancer after radiation therapy for pelvic cancer. Front. Oncol. 2020, 10, 584072.
  19. Brenner, D.J.; Curtis, R.E.; Hall, E.J.; Ron, E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000, 88, 398–406.
  20. Grantzau, T.; Overgaard, J. Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients. Radiother. Oncol. 2015, 114, 56–65.
  21. Yap, J.; Chuba, P.J.; Thomas, R.; Aref, A.; Lucas, D.; Severson, R.K.; Hamre, M. Sarcoma as a second malignancy after treatment for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 1231–1237.
  22. Tward, J.D.; Wendland, M.M.M.; Shrieve, D.C.; Szabo, A.; Gaffney, D.K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006, 107, 108–115.
  23. Chaturvedi, A.K.; Engels, E.A.; Gilbert, E.S.; Chen, B.E.; Storm, H.; Lynch, C.F.; Hall, P.; Langmark, F.; Pukkala, E.; Kaijser, M.; et al. Second cancers among 104,760 survivors of cervical cancer: Evaluation of long-term risk. J. Nat. Cancer Inst. 2007, 99, 1634–1643.
  24. Charas, T.; Taggar, A.; Zelefsky, M.J. Second malignancy risk in prostate cancer and radiotherapy. Future Oncol. 2017, 13, 385–389.
  25. Hamada, N.; Fujimichi, Y. Classification of radiation effects for dose limitation purposes: History, current situation and future prospects. J. Radiat. Res. 2014, 55, 629–640.
  26. West, C.M.; Barnett, G.C. Genetics and genomics of radiotherapy toxicity: Towards prediction. Genome Med. 2011, 3, 52.
  27. Taitt, H.E. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am. J. Mens Health 2018, 12, 1807–1823.
  28. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
  29. Baxter, N.N.; Tepper, J.E.; Durham, S.B.; Rothenberger, D.A.; Virnig, B.A. Increased risk of rectal cancer after prostate radiation: A population-based study. Gastroenterology 2005, 128, 819–824.
  30. Rombouts, A.J.M.; Hugen, N.; Elferink, M.A.G.; Poortmans, P.M.P.; Nagtegaal, I.D.; De Wilt, J.H.W. Increased risk for second primary rectal cancer after pelvic radiation therapy. Eur. J. Cancer 2020, 124, 142–151.
  31. Huo, D.; Hetzel, J.T.; Roy, H.; Rubin, D.T. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1979–1985.
  32. Hinnen, K.A.; Schaapveld, M.; Van Vulpen, M.; Battermann, J.J.; Van der Poel, H.; Van Oort, I.M.; Van Roermund, J.G.H.; Monninkhof, E.M. Prostate brachytherapy and second primary cancer risk: A competitive risk analysis. J. Clin. Oncol. 2011, 29, 4510–4515.
  33. Murray, L.; Henry, A.; Hoskin, P.; Siebert, F.-A.; Venselaar, J.; PROBATE group of GEC ESTRO. Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. Radiother. Oncol. 2014, 110, 213–228.
  34. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337.
  35. Yaeger, R.; Chatila, W.K.; Lipsyc, M.D.; Hechtman, J.F.; Cercek, A.; Sanchez-Vega, F.; Jayakumaran, G.; Middha, S.; Zehir, A.; Donoghue, M.T.A.; et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 2018, 33, 125–136.e3.
  36. Chatila, W.K.; Kim, J.K.; Walch, H.; Marco, M.R.; Chen, C.-T.; Wu, F.; Omer, D.M.; Khalil, D.N.; Ganesh, K.; Qu, X.; et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat. Med. 2022, 28, 1646–1655.
  37. Pino, M.S.; Chung, D.C. The chromosomal instability pathway in colon cancer. Gastroenterology 2010, 138, 2059–2072.
  38. Hasan, S.; Renz, P.; Wegner, R.E.; Finley, G.; Raj, M.; Monga, D.; McCormick, J.; Kirichenko, A. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: A national cancer database (NCDB) analysis. Ann. Surg. 2020, 271, 716–723.
  39. Tsuji, T.; Sawai, T.; Nakagoe, T.; Hidaka, S.; Shibasaki, S.; Tanaka, K.; Nanashima, A.; Yamaguchi, H.; Yasutake, T.; Tagawa, Y. Genetic analysis of radiation-associated rectal cancer. J. Gastroenterol. 2003, 38, 1185–1188.
  40. Narui, K.; Ike, H.; Fujii, S.; Nojiri, K.; Tatsumi, K.; Yamagishi, S.; Saito, S.; Kunisaki, C.; Imada, T.; Nozawa, A.; et al. A case of radiation-induced rectal cancer. Nippon. Shokakibyo Gakkai Zasshi 2006, 103, 551–557.
  41. Majumdar, S.R.; Fletcher, R.H.; Evans, A.T. How does colorectal cancer present? Symptoms, duration, and clues to location. Am. J. Gastroenterol. 1999, 94, 3039–3045.
  42. Porouhan, P.; Farshchian, N.; Dayani, M. Management of radiation-induced proctitis. J. Fam. Med. Prim. Care 2019, 8, 2173–2178.
  43. US Preventive Services Task Force; Davidson, K.W.; Barry, M.J.; Mangione, C.M.; Cabana, M.; Caughey, A.B.; Davis, E.M.; Donahue, K.E.; Doubeni, C.A.; Krist, A.H.; et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 2021, 325, 1965–1977.
  44. NCCN Survivorship. Available online: http://www.nccn.org/ (accessed on 20 May 2022).
  45. Zelefsky, M.J.; Pei, X.; Teslova, T.; Kuk, D.; Magsanoc, J.M.; Kollmeier, M.; Cox, B.; Zhang, Z. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: Incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012, 110, 1696–1701.
  46. Nakamura, Y.; Soma, T.; Izumi, K.; Sakai, Y.; Ushijima, H.; Kudo, S.; Saito, Y.; Kageyama, Y. Screening of chronic radiation proctitis and colorectal cancer using periodic total colonoscopy after external beam radiation therapy for prostate cancer. Jpn. J. Clin. Oncol. 2021, 51, 1298–1302.
  47. Tamai, O.; Nozato, E.; Miyazato, H.; Isa, T.; Hiroyasu, S.; Shiraishi, M.; Kusano, T.; Muto, Y.; Higashi, M. Radiation-associated rectal cancer: Report of four cases. Dig. Surg. 1999, 16, 238–243.
  48. Goldner, G.; Tomicek, B.; Becker, G.; Geinitz, H.; Wachter, S.; Zimmermann, F.; Wachter-Gerstner, N.; Reibenwein, J.; Glocker, S.; Bamberg, M.; et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 78–83.
  49. Moreno, C.C.; Sullivan, P.S.; Mittal, P.K. MRI evaluation of rectal cancer: Staging and restaging. Curr. Probl. Diagn. Radiol. 2017, 46, 234–241.
  50. Garcia-Aguilar, J.; Renfro, L.A.; Chow, O.S.; Shi, Q.; Carrero, X.W.; Lynn, P.B.; Thomas, C.R.; Chan, E.; Cataldo, P.A.; Marcet, J.E.; et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): Results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015, 16, 1537–1546.
  51. Garcia-Aguilar, J.; Patil, S.; Gollub, M.J.; Kim, J.K.; Yuval, J.B.; Thompson, H.M.; Verheij, F.S.; Omer, D.M.; Lee, M.; Dunne, R.F.; et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J. Clin. Oncol. 2022, 40, 2546–2556.
  52. Mohiuddin, M.; Marks, G.; Marks, J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002, 95, 1144–1150.
  53. Haddock, M.G.; Gunderson, L.L.; Nelson, H.; Cha, S.S.; Devine, R.M.; Dozois, R.R.; Wolff, B.G. Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 1267–1274.
  54. Kamran, S.C.; Zelefsky, M.; Nguyen, P.L.; Lawton, C.A.F. To Radiate or Not to Radiate-The Challenges of Pelvic Reirradiation. Semin. Radiat. Oncol. 2020, 30, 238–241.
  55. Hom, D.B.; Adams, G.L.; Monyak, D. Irradiated soft tissue and its management. Otolaryngol. Clin. N. Am. 1995, 28, 1003–1019.
  56. Viswanathan, A.N.; Lee, L.J.; Eswara, J.R.; Horowitz, N.S.; Konstantinopoulos, P.A.; Mirabeau-Beale, K.L.; Rose, B.S.; Von Keudell, A.G.; Wo, J.Y. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer 2014, 120, 3870–3883.
  57. Ashburn, J.H.; Kalady, M.F. Radiation-Induced Problems in Colorectal Surgery. Clin. Colon Rectal Surg. 2016, 29, 85–91.
  58. Valentini, V.; Morganti, A.G.; Gambacorta, M.A.; Mohiuddin, M.; Doglietto, G.B.; Coco, C.; De Paoli, A.; Rossi, C.; Di Russo, A.; Valvo, F.; et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 1129–1139.
  59. Morganti, A.G.; Santoni, R.; Osti, M.F. Radiotherapy in pelvic recurrences of rectal cancer. Ann. Ital. Chir. 2001, 72, 585–594.
  60. Romesser, P.B.; Crane, C.H. Chemo-Re-Irradiation and Salvage Surgery for Locally Recurrent Rectal Cancer. Ann. Surg. Oncol. 2021, 28, 4769–4771.
  61. Van der Meij, W.; Rombouts, A.J.M.; Rütten, H.; Bremers, A.J.A.; De Wilt, J.H.W. Treatment of locally recurrent rectal carcinoma in previously (chemo)irradiated patients: A review. Dis. Colon Rectum 2016, 59, 148–156.
  62. Lee, S.-H.; Hernandez de Anda, E.; Finne, C.O.; Madoff, R.D.; Garcia-Aguilar, J. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision. Dis. Colon Rectum 2005, 48, 2249–2257.
  63. Hung, H.; You, J.; Chiang, J.; Hsieh, P.; Chiang, S.; Lai, C.; Tasi, W.; Yeh, C.; Chern, Y.; Hsu, Y. Clinicopathological characteristics and outcomes of metachronous rectal cancer in patients with a history of cervical cancer with and without remote radiotherapy: Reports of 45 cases. Medicine 2020, 99, e21328.
  64. Shadad, A.K.; Sullivan, F.J.; Martin, J.D.; Egan, L.J. Gastrointestinal radiation injury: Prevention and treatment. World J. Gastroenterol. 2013, 19, 199–208.
  65. Quinn, T.J.; Daignault-Newton, S.; Bosch, W.; Mariados, N.; Sylvester, J.; Shah, D.; Gross, E.; Hudes, R.; Beyer, D.; Kurtzman, S.; et al. Who benefits from a prostate rectal spacer? secondary analysis of a phase III trial. Pract. Radiat. Oncol. 2020, 10, 186–194.
  66. Mariados, N.; Sylvester, J.; Shah, D.; Karsh, L.; Hudes, R.; Beyer, D.; Kurtzman, S.; Bogart, J.; Hsi, R.A.; Kos, M.; et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2015, 92, 971–977.
  67. Miller, L.E.; Efstathiou, J.A.; Bhattacharyya, S.K.; Payne, H.A.; Woodward, E.; Pinkawa, M. Association of the Placement of a Perirectal Hydrogel Spacer with the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw. Open 2020, 3, e208221.
  68. Xiang, M.; Chang, D.T.; Pollom, E.L. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. Cancer 2020, 126, 3560–3568.
  69. Hassan Osman, M.; Mehiri, N.; Chérif, J.; Zouaoui, A.; Toujani, S.; Louzir, B.; Haouet, S.; Menif, E.; Doghfous, J.; Béji, M. Multifocal epithelioid haemangioendothelioma. Tunis. Med. 2009, 87, 637.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback